Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape

Follicular lymphoma (FL) is the second most common type of non-Hodgkin’s lymphoma. FL is an incurable disease with treatment options ranging from a “watch-and-wait” approach to localized therapy with radiation or systemic therapy with rituximab in combination with chemotherapy regimens. This review...

Descripción completa

Detalles Bibliográficos
Autores principales: Subramanian, Janakiraman, Cavenagh, Jamie, Desai, Bhardwaj, Jacobs, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411111/
https://www.ncbi.nlm.nih.gov/pubmed/28479860
http://dx.doi.org/10.2147/CMAR.S120589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411111/
https://www.ncbi.nlm.nih.gov/pubmed/28479860
http://dx.doi.org/10.2147/CMAR.S120589

Ejemplares similares